Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PuraPharmHKSE:01498 23 Median PS Value is HK$0.57 as of Aug. 20, 2026, which is 100% below its 10-year median of 0.71. GuruFocus rates HKSE:01498 with a GF Score™ of 23/100 and a GF Value™ of HK$0.51 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 551 Drug Manufacturers companies, PuraPharm ranks better than 82.58% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. PuraPharm's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.806. PuraPharm's 10-Year median PS Ratio is 0.7072. Therefore, the Median PS Value for today is HK$0.57.
As of today (2026-08-20), PuraPharm's share price is HK$0.28. PuraPharm's Median PS Value is HK$0.57. Therefore, PuraPharm's Price to Median PS Value for today is 0.49.
The historical rank and industry rank for PuraPharm's Median PS Value or its related term are showing as below:
HKSE:01498'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48 Med: 0.71 Max: 0.8
Current: 0.49
During the past 12 years, the highest Price to Median PS Value of PuraPharm was 0.80. The lowest was 0.48. And the median was 0.71.
HKSE:01498's Price-to-Median-PS-Value is ranked better than 82.58% of 551
companies
in the Drug Manufacturers industry
Industry Median: 0.87
vs HKSE:01498: 0.49
PuraPharm (HKSE:01498) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
PuraPharm's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.28
/
0.57
=
0.49
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuraPharm Median PS Value Related Terms
PuraPharm Median PS Value Historical Data
* Premium members only.
The historical data trend for PuraPharm's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuraPharm Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PuraPharm's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where PuraPharm's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.7072.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PuraPharm's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.806.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuraPharm (HKSE:01498) has a Median PS Value of HK$0.57 as of Aug. 20, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on PuraPharm and its competitors. This is 20% below median its historical median of 0.71. Over the past decade, PuraPharm's Median PS Value has ranged from 0.48 to 0.80. According to the industry distribution chart, PuraPharm ranks #96 out of 551 companies in the Drug Manufacturers industry, placing it in the top 17.4%.
Is PuraPharm's Median PS Value too high?
PuraPharm's current Median PS Value of HK$0.57 is 20% below median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 0.80. Based on the distribution chart, PuraPharm ranks #96 out of 551 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PuraPharm has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PuraPharm's Median PS Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PuraPharm ranks #96 out of 551 companies for Median PS Value. This places PuraPharm in the top 17% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.87. Historically, PuraPharm's own Median PS Value has ranged from 0.48 to 0.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.87, based on 551 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on PuraPharm and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PuraPharm's current Median PS Value is HK$0.57, which is 20% below median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuraPharm stock overvalued right now?
Based on GuruFocus' analysis, PuraPharm (HKSE:01498) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.51, compared to a current price of HK$0.28 — trading 45.1% below its estimated fair value. The current Median PS Value is HK$0.57, which is 20% below median its 10-year median of 0.71. PuraPharm's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For PuraPharm (HKSE:01498), the current Median PS Value is HK$0.57 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuraPharm (HKSE:01498) Overvalued in 2026?
Based on GuruFocus' analysis, PuraPharm stock appears to be undervalued.
The current stock price of HK$0.28 is trading 45.1% below its estimated GF Value™ of HK$0.51.
GuruFocus considers PuraPharm to be Possible Value Trap.
Key valuation signals for HKSE:01498:
Median PS Value: HK$0.57 (20% below median its 10-year median of 0.71)
GF Value™: HK$0.51 vs. price of HK$0.28 (45.1% below fair value)
No single metric tells the full story. See the HKSE:01498 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuraPharm Corporation Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, production, and sale of concentrated Chinese medicine granules (CCMG) and other Chinese healthcare products. Its operations also include the cultivation and trading of raw Chinese herbs, the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces, and the provision of Chinese medical diagnostic services. The Group's reportable operating segments are: China CCMG, Hong Kong CCMG, Chinese healthcare products, Clinics, and Plantation. Maximum revenue is derived from the Hong Kong CCMG segment. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from the Chinese Mainland and other countries.
23GF Score
Get the complete analysis for HKSE:01498
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01498 has been successfully added to your 
